2023
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed diagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere formHepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
Kim J, Newcomb C, Carbonari D, Torgersen J, Althoff K, Kitahata M, Klein M, Moore R, Reddy K, Silverberg M, Mayor A, Horberg M, Cachay E, Lim J, Gill M, Chew K, Sterling T, Hull M, Seaberg E, Kirk G, Coburn S, Lang R, McGinnis K, Gebo K, Napravnik S, Kim H, Re V, Research and Design of IeDEA F. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016. PLOS ONE 2023, 18: e0290889. PMID: 37656704, PMCID: PMC10473492, DOI: 10.1371/journal.pone.0290889.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationUndetectable HBV DNAHBV coinfectionHBV DNACare cascadeCohort CollaborationViral suppressionHIV/HBV coinfectionTenofovir-based antiretroviral therapyHIV/HBVAntiretroviral therapy regimenCross-sectional studyDelivery of careHBV therapyHBV treatmentHBV viremiaAntiretroviral therapyHBV infectionHIV infectionTherapy regimenChronic infectionClinical cohortCoinfectionTherapyInfection
2017
Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Digestive Diseases And Sciences 2017, 63: 61-71. PMID: 29177849, DOI: 10.1007/s10620-017-4850-1.Peer-Reviewed Original ResearchConceptsCommunity oncology clinicsCommunity teaching hospitalHBV screening rateOncology clinicTeaching hospitalHBV infectionScreening ratesCancer chemotherapyUniversity HospitalChronic hepatitis B virus infectionHepatitis B virus infectionHepatitis B Virus ScreeningHBV reactivation riskChronic HBV infectionB virus infectionHBV core antibodyHBV surface antigenAdult cancer patientsRisk of reactivationHospital networkLarge university hospitalCore antibodyHBV exposureHBV screeningBackgroundCancer patients
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian duration
2014
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology 2014, 148: 215-219. PMID: 25447850, DOI: 10.1053/j.gastro.2014.10.039.Peer-Reviewed Original Research